Papers by Elliott M. Antman
Page 2 · newest first
- Ideal Cardiovascular Health in Young Adults With Established Cardiovascular DiseasesFrontiers in Cardiovascular Medicine · 2022
- Sodium and Health: Old Myths and a Controversy Based on DenialCurrent Nutrition Reports · 2022
- Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent PlasmaJAMA Network Open · 2022
- Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroupsAmerican Heart Journal · 2022
- The inclusion of augmented intelligence in medicine: A framework for successful implementationCell Reports Medicine · 2022
- Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48European Heart Journal - Cardiovascular Pharmacotherapy · 2021
- Exploring patient experiences coping with using multiple medications: a qualitative interview studyBMJ Open · 2021
- A precision medicine approach to sex-based differences in ideal cardiovascular healthScientific Reports · 2021
- Ideal Cardiovascular Health in Former SmokersJournal of Clinical Medicine · 2021
- Comparative Effectiveness of Aspirin Dosing in Cardiovascular DiseaseNew England Journal of Medicine · 2021
- Obesity and Ideal Cardiovascular Health: Results from the My Research Legacy StudyObesities · 2021
- Nonprofit Advocacy at the American Heart Association: Creating a Visionary Way Forward at Our 40th Anniversary: An American Heart Association Policy StatementCirculation · 2021
- Data from Digital Health Devices Informs Ideal Cardiovascular HealthJournal of Personalized Medicine · 2021
- Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial FibrillationJournal of the American College of Cardiology · 2021
- Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trialEuropean Heart Journal · 2021
- The path to universalityEuropean Journal of Heart Failure · 2021
- Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 TrialCirculation · 2021
- Sex, Permanent Drug Discontinuation, and Study Retention in Clinical TrialsCirculation · 2021
- Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 studyAmerican Heart Journal · 2021
- Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic DiseaseCirculation · 2020
- Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF–TIMI 48 TrialCirculation Cardiovascular Quality and Outcomes · 2020
- A Biomarker-Centric Approach to Drug Discovery and Development: Lessons Learned from the Coronavirus Disease 2019 PandemicJournal of Pharmacology and Experimental Therapeutics · 2020
- Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58 634 patients across four randomized controlled trialsEuropean Heart Journal - Cardiovascular Pharmacotherapy · 2020
- Comprehensive characterization of protein-protein interaction network perturbations by human disease mutations2020
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 TrialThrombosis and Haemostasis · 2020
- Pooling Data From Individual Clinical Trials in the COVID-19 EraJAMA · 2020
- Managing Stable Ischemic Heart DiseaseNew England Journal of Medicine · 2020
- Left Atrial Structure and Function and the Risk of Death or Heart Failure in Atrial FibrillationEuropean Journal of Heart Failure · 2019
- Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trialEuropean Heart Journal - Cardiovascular Pharmacotherapy · 2019
- Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 TrialCirculation · 2019
- ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction).2019
- Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 TrialHypertension · 2019
- Individual Patient-Level Data Sharing for Continuous Learning: A Strategy for Trial Data SharingNAM Perspectives · 2019
- Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48Circulation · 2019
- Improving Care of STEMI in the United States 2008 to 2012Journal of the American Heart Association · 2018
- Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trialEuropean Heart Journal · 2018
- Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trialEuropean Heart Journal · 2018
- Fourth universal definition of myocardial infarction (2018)Kardiologia Polska · 2018
- The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trialsEuropean Heart Journal Acute Cardiovascular Care · 2018
- Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trialsEuropean Heart Journal · 2018
- Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 TrialSHILAP Revista de lepidopterología · 2018
- Improving care at the population and individual level: lessons from SWEDEHEARTEuropean Heart Journal · 2018
- Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF–TIMI 48European Heart Journal Acute Cardiovascular Care · 2018
- Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 TrialCirculation · 2018
- Gastrointestinal Bleeding With Edoxaban Versus WarfarinCirculation Cardiovascular Quality and Outcomes · 2018
- American Heart Association Principles on the Accessibility and Affordability of Drugs and BiologicsCirculation · 2017
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSEuropean Heart Journal · 2017
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSEuropean Journal of Cardio-Thoracic Surgery · 2017
- Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 TrialJournal of the American Heart Association · 2017
- Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF‐TIMI 48 TrialJournal of the American Heart Association · 2017